Effective cancer treatment is crucially dependent on the identification of the biological processes that drive a tumor. However, multiple processes may be active simultaneously in a tumor. Clustering is inherently unsuitable to this task as it assigns a tumor to a single cluster. In addition, the wide availability of multiple data types per tumor provides the opportunity to profile the processes driving a tumor more comprehensively.
Introduction
Cancer is a heterogeneous disease, both at the molecular level and in response to 2 treatment. If we can better understand the variation between tumors, we may get a 3 better understanding of why tumors respond differently to treatment. This could, in 4 turn, lead to better treatment selection for patients. 5 To chart the variation across tumors, projects such as The Cancer Genome Atlas 6 (TCGA) have collected a variety of molecular data from thousands of tumors [1] [2] [3] . 7 Analyses of these data provide a better understanding of the underlying biological 8 processes associated with the cancer. For example, recurrent copy number 9 aberrations or recurrent point mutations may reveal the drivers of carcinogenesis. (FuncSFA) . The green circles represent the factors, and the red, blue and yellow circles at the bottom represent the observed variables, with the colors representing the data types and each circle representing an individual variable (i.e. the expression of a gene or protein, or the copy number of a gene). The black lines connecting the individual variables to the factors represent the regression coefficients. B: Graphical representation of the mathematical concepts of SFA with X representing the N × n data matrix, Z the N × k obtained factor matrix and B the k × n factor coefficients. C: Graphical representation of the computations of the factor expression coefficients. The coefficients represented by the k × n m matrix C are obtained by regressing the N × n m RNA expression matrix, X m , on the N × k factor matrix Z. D: The gene-set enrichment analysis designed to assign biological processes or pathways to the obtained factors. E: Application of the factors to determine the activity of the factors (or associated biological processes) in a new tumor. (N: number of tumors; n: number of features; k: number of factors; n m : number of mRNA features; Z: factor matrix; X: data matrix (concatenation of mRNA, copy number and Reverse Phase Protein Array (RPPA) data); B: Sparse factor coefficients; C: Factor regression coefficients; GSEA: Gene-set enrichment analysis).
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represented by an independent factor. In lung cancer, which has remained largely 75 uncharacterized, we also identified an EMT and Immune factor, as well as a factor 76 associated with the main lung subtypes-Adenocarcinoma and Squamous Cell 77 Carcinoma. We also identified a factor which captures the activation of the 78 transcription factor NFE2L2. Here the power of integration of multiple data types is 79 highlighted by the fact that the activity of this factor is associated with mutations in 80 NFE2L2 as well as its inhibitor KEAP. We expect that the identified factors not only 81 provide a more complete characterization of the biological processes active in the 82 different tumors, but will also provide a starting point for the development of better 83 treatment strategies. sample. In this section we discuss each of these components.
93
Sparse-factor analysis 94 In our sparse-factor analysis, we assume that each tumor type is characterized by a 95 set of key driving factors, or biological processes, that give rise to molecular 96 phenotypes. These driving factors cannot be measured directly, but are observed 97 indirectly through noisy measurements of multiple molecular data types such as 98 mRNA expression, copy number aberrations and protein expression and modification.
99
The challenge is to employ all these measured data types simultaneously to identify 100 this unobserved structure in the data.
101
Sparse-factor analysis addresses this challenge by modeling the unobserved 102 structure by a relatively small number of continuous factors-the green circles in analysis. Consequently, a factor is defined by the subset of molecular variables that 120 contribute to that factor as well as the regression coefficients that model the degree to 121 which each molecular variable contributes to the factor.
122
Sparsity of regression coefficients induced by the elastic net penalty improves data 123 integration by preventing one data type (especially mRNA expression) from 124 dominating the analysis. A larger penalty can be applied to mRNA expression to the 125 other data types, keeping mRNA expression under control. Sparse weights are also 126 biologically plausible as a biological process might involve the altered expression of 127 thousands of genes but is unlikely to be driven by all genes.
128
The joint likelihood is maximized using an expectation maximization algorithm. This 129 algorithm improves over the iCluster2 algorithm [11] by rescaling the factors to unit 130 variance and by estimating coefficients with coordinate descent [15] ). On the TCGA 131 breast cancer dataset our algorithm converged faster and to better solutions than the 132 iCluster2 algorithm (S1 Fig) .
133
A very important feature of FuncSFA is that, unlike iCluster, we do not force a tumor 134 assignment to discrete clusters, but represent the level of activity of each of the 135 driving factors in a given tumor. Consequently, each tumor can be a 'member' of 136 multiple factors, and this 'membership' can also vary in strength.
137

Gene-set enrichment analysis 138
While sparse-factor analysis efficiently identifies the hidden driving factors, it remains 139 challenging to directly attach biological interpretation to the identified factors. In some 140 cases, such as ERBB2 pathway activation, this may be straightforward, but in many 141 other cases this remains very challenging. One of our important contributions is the 142 development of a gene-set enrichment analysis tailored to the results of sparse-factor 143 analysis.
144
The first step of the gene-set enrichment analysis is to regress the factors on the gene 145 expression matrix ( Fig 1C) . This may sound counter-intuitive, as the purpose of the 146 SFA is to pinpoint the genes contributing to the factor, hence revealing the underlying 147 drivers. However, the motivation for this is two-fold. First, the sparsity constraints on 148 the coefficients introduce zeros in the coefficients. Although this is beneficial for 149 human interpretation and driver identification, genes with zero coefficients can not be 150 ranked in terms of their contribution to the factors. This is a major complicating factor 151 as such a gene ranking is an essential part of the gene-set enrichment analysis.
152
Second, RNA expression remains a data type that captures most of the variation in 153 the cell, and can, as such be quite informative regarding the activity of biological 154 processes and hence for the interpretation of the factors. So, having gone through the 155 process of identifying driving factors that are robust, in the sense that they are 156 common to all data types, we employ the regression of the factors to the complete the factor expression coefficients and compute the enrichment statistic for every 163 gene-set factor pair ( Fig 1D) [10] . We determined statistical significance of the 164 enrichments by a sample permutation test [10] . The enrichment results provide input 165 for a manual curation and verification process to identify the most likely biological 166 process that gives rise to the identified factors. 
173
Application to breast and lung cancer 174 We have applied FuncSFA to the breast cancer [1] and lung cancer [2, 3] data sets 175 from TCGA. Breast cancer is arguably the most exhaustively subtyped type of cancer, 176 and hence serves as a very good positive control for FuncSFA [1, 12, 16, 17] . Lung 177 cancer has not been studied so extensively, even though at the moment it is the For both datasets, we used three data types: DNA copy number, protein expression 184 measured by RPPA, and RNA expression. First, we included DNA copy number at 185 162 (breast) or 213 (lung) frequently aberrated loci from SNP6 arrays as identified by 186 RUBIC [18] . This DNA copy number data set is clearly important as it captures many 187 copy number events that may have a functional role in oncogenesis. Second, we 188 included protein expression and modification recorded by RPPA with 195 (breast) or 189 216 (lung) protein epitopes. These measurements capture the activity of key signaling 190 events in pathways which play a central role in many cancer types, including those 191 under study here. Third, we included RNA expression of the 1000 most variable 192 genes as measured by RNAseq. We selected the 1000 most variable genes to reduce 193 noise in the data and to reduce the complexity of the model. We included RNA For both breast and lung cancer, we employed the abovementioned data types and 201 applied FuncSFA. We specifically set out to find the ten strongest factors. We chose Second, most subtyping approaches that have been applied to date revealed ten or 207 fewer subtypes: five intrinsic subtypes in breast cancer [19, 20] ten IC10 subtypes in 208 breast cancer [12] , four consensus subtypes in colorectal cancer [5] , four in 209 squamous cell carcinoma [21] and three in lung adenocarcinoma [22] ). Therefore, our 210 assumption was that ten factors would be sufficient to capture the strongest (known) 211 factors, while leaving room for the discovery of new biological processes without 212 running the risk of compromising the robustness of the factors being discovered by 213 having a too large factor-to-sample-size ratio.
214
Breast Cancer 215 We applied FuncSFA to the breast cancer data employing 10 factors based on the 216 arguments given above. We performed functional annotation of the factors, as Table) . This resulted in the following 10 factors: ER (Estrogen Receptor), strongest sparse-factor analysis coefficients (from the B matrix in Fig 1B) for the three 224 data types are represented in Fig 2. We will first provide some general observations of 225 the results and then provide a detailed description and analysis of each factor. 226 From the coefficients depicted in Fig 2, we make the following global observations.
227
First, the ER factor is strongly associated with both mRNA and protein expression of 228 ESR1, GATA3, PGR and AR, as expected. Second, the EMT factor shows strong 229 association with THBS2 and COL11A1 expression-the genes identified by 230 Anastassiou and colleagues [23] (see also the more detailed description of the EMT 231 factor below). In addition, the EMT factor shows association with many collagens.
232
Third, the HER2 factor shows the expected strong association with ERBB2 copy 233 number gain and protein upregulation, GRB7 copy number gain as well as EGFR 234 protein upregulation. Fourth, the Basal factor shows strong association with the RNA 235 expression of basal keratins and finally, 8q-gained shows concordant copy number 236 and expression changes for a number of genes located on Chromosome 8q, including 237 SGK3, MYC and TP52INP1. explained by a given factor mostly being the variation in gene expression. There are a 242 few exceptions. The HER2, Luminal proliferative and 8q-gained factors, explain more 243 variation in copy number data than in RNA expression data. For HER2 and 8q-gained 244 tumors this is not surprising as they are clearly copy number driven (Fig 2 and 4) .
245
Most strikingly, the Techical-RPPA factor explains a very large proportion of the 246 variation in the RPPA data. However, as the name indicates this factor most likely 247 captures technical variation in the RPPA data, as this variation is not reflected in the 248 other data types, and as the gene-set enrichment analysis does not reveal a clear 249 functional enrichment associated with this factor. Similarly, the Technical-RNA factor 250 explains technical variation in the RNAseq data. The ER factor is unique in the sense 251 that it is the single factor that explains most variation in RNA expression and RPPA The strongest sparse-factor analysis coefficients for the breast cancer data set for each of the three data types and all ten factors. The height of the bars shows the values of the coefficients. If a gene is strongly associated with a factor, we show all coefficients of that gene in the model. RNA expression coefficients are shown in blue. Protein expression coefficients are shown in orange. Any modifications of an epitope are noted in a short text description: pX = phosphorylated at residue X; clX = cleaved at residue X. DNA copy number coefficients are shown in red. Numbers refer to the recurrently aberrated loci in S3 Table. Recurrent gains are prefixed with a g, losses with an l.
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data (apart from the Technical-RPPA factor). This is not unexpected as ER signaling 253 arguably drives the most important subtype distinction in breast cancer: the one 254 between ER-positive and ER-negative tumors. In the remainder of this section, we will 255 discuss each of the identified factors in greater detail.
256
Intrinsic subtypes are covered by factors 257 The intrinsic subtypes proposed by Perou and Sørlie represent one of the earliest and 258 most widely used subtypings of breast cancer [17, 19, 20] . This discrete classification 259 of breast cancer in five subtypes (Her2-enriched, Basal-like, Luminal A, Luminal B and 260 Normal-like) is typically performed by applying a nearest centroid classifier to the RNA 261 expression profile of the tumor to be subtyped. To perform this classification based on 262 mRNA expression, Parker and colleagues developed a a 50 gene signature, the 263 so-called PAM50 [4] . As the PAM50 subtyping is widely acknowledged as a gold 264 standard in breast cancer subtyping, we set out to check whether the variation 265 captured by the PAM50 subtyping is also recapitulated by the FuncSFA factors. To this 266 end we applied the PAM50 subtyping to the breast cancer cohort and compared the 267 PAM50 subtyping to the variation captured by the FuncSFA factors. Fig 3B. 1 depicts a 268 t-SNE map of the breast cancer tumors with the PAM50 subtype assignment indicated 269 by the colors. Four FuncSFA factors capture the variation in the PAM50 subtypes.
270
First, the ER factor is associated with both mRNA and protein expression of ESR1, AR 271 and PR (Fig 2) , and is enriched for gene signatures of ESR1 expression and the Table) . This suggests that this factor represents the Second, the HER2 factor shows large SFA coefficients for ERBB2 protein expression 284 and copy number gain ( Fig 2) . The gene-set enrichment analysis shows enrichment 285 for signatures of ERBB2 amplification and the HER2-enriched PAM50 subtype.
286
Importantly, this factor is strongly associated with the amplicon on Chromosome 17 287 harboring ERBB2 and GRB7, as evidenced by the large coefficients identified for this 288 amplicon in the factor analysis (Fig 2 and 4) . Taken together, this suggest that the 289 HER2-factor indeed identifies the HER2+ tumors. This is confirmed by the strong 290 association of this factor with the HER2-enriched PAM50 subtype ( Fig 3B. 3,
291
AUC=0.96) and by the large weights of the HER2/GRB7 locus on DNA copy number 292 ( Fig 4) . EMT is a process frequently associated with cancer [24] and it involves multiple 313 regulators, including SNAI1, SNAI2, TWIST1 and ZEB1 as well as their targets [25] .
314
The gene-set enrichment analysis revealed an association of one of the factors with 315 EMT and the extracellular matrix (S1 developed to detect various forms of EMT (For example, see [26] ). Based on the 321 gene-set enrichment analysis, the strongest association of the EMT factor is with a 322 12/30 consensus EMT signature proposed by Anastassiou and colleagues [23] . They 323 compiled a pan-cancer EMT signature from multiple public data sets by comparing 324 metastatic with non-metastatic tumors [27] . As an EMT-like expression profile can be 325 associated with stromal contamination in a tumor sample, Anastassiou and colleagues 326 profiled human tumors from a PDX model on a microarray with species-specific 327 probes. This enabled the removal of the mouse stromal signal and revealed that the 328 signature is tumor specific. A strong correlation between the EMT factor and the sum 329 of the two most important genes in this signature (Fig 5A, ρ=0 .89) confirms the 330 interpretation of this factor as capturing the specific type of EMT modeled by the 331 Anastassiou signature.
332
While the claudin-low and metaplastic subtypes of breast cancer have been 333 associated with EMT [28] , larger studies failed to confirm the presence of the Immune factor 343 The Immune factor shows enrichment for Interferon-Alpha Response and other 344 immune related signatures (S1 Table and S1 Table) . In order to shed further light on 345 13/30 this factor we employed publicly available Cibersort scores [29] to estimate the FuncSFA to the lung tumor data from the TCGA in order to further assess its 380 usefulness in uncovering new and clinically relevant biology. We merged the TCGA 381 lung adenocarcinoma and lung squamous cell carcinoma datasets to obtain a data set 382 that is comparable in size to the breast cancer set. We employed the same data types 383 (gene expression, RPPA and copy number) as we employed in the breast cancer 384 analysis. As the dataset is of comparable size to the breast cancer dataset, and as 385 Wilkerson and colleagues defined a total of 7 lung cancer subtypes [21, 22] we set out 386 to identify 10 factors. This allows the capturing of known variation with some room for 387 the discovery of novel subtypes. Fig 1) for the three data types are represented in Fig 6. As before we will first 394 provide some general observations of the results and then provide a detailed 395 description and analysis of each factor.
396
The coefficients depicted in Fig 6 reveal the following. First, as before, the EMT factor 397 shows strong association with the Anastassiou signature genes (THBS2 and 398 COL11A1) as well as a number of collagens. Second, the Mitochondrial factor has 399 large SFA coefficients for genes encoded on the mitochondrial DNA while the 400 Translation factor shows strong association with genes encoding ribosomal proteins.
401
Third, the BSCC and 8p11-gained factors show large RPPA coefficients, with a 402 concentration of lowly expressed proteins in the PI3K pathway. However, they do 403 differ in terms of their RNA expression coefficients, and we will provide more elaborate 404 descriptions of these factors below. Fourth, the Immune factor is characterized by these two factors together are much smaller than the RPPA values predicted by one 422 of these factors on its own.
423
In the remainder of this section, we will first discuss the Wilkerson subtypes that have 424 been proposed for lung cancer. Then we will discuss each of the identified factors in 425 greater detail.
426
The Wilkerson molecular subtypes of lung cancer 427 The molecular subtypes of lung adenocarcinoma and lung squamous carcinoma were 428 defined by Wilkerson and colleagues [21, 22] , and also found to be present on the 429 larger TCGA datasets [2, 3] . Fig 7B.2 TERC  FGFR1  MYC  12p12.3  14q13  15q26  TBC1D1  IRF2 9p23-21   PTPRD  CCDC171  SLC24A2 PEX11G  ARGHEF18   CECR2   22q13.31-32  NSD3 Recurrently aberrated copy number regions are annotated with chromosomal bands or putative driver genes in the region. specific subtypes of breast cancer. Rather, it seems that the Wilkerson subtypes are 438 driven by a complex interplay of multiple, heterogeneous biological processes. Under 439 these circumstances, we would not expect to find factors that represent the subtypes 440 directly, but that the factors should capture the underlying biological processes.
441
Adenocarinoma and squamous cell carcinoma were subtyped separately, so we have 442 a set of subtypes for each. The adenocarcinoma subtypes are termed 'terminal 443 respiratory unit' (TRU), 'proximal-inflammatory' (PI) and 'proximal-proliferative' (PP).
444
The TRU subtype is characterized by highly expressed asthma, excretion and 445 surfactant genes, the PP subtype with the overexpression of defense response genes 446 (chemokines) and the PI subtype with high expression of DNA-repair genes [22] . The 447 Wilkerson squamous cell carcinoma subtypes are termed 'Basal', 'Classical', 448 'Secretory' and 'Primitive'. The Basal subtype has been associated with cell adhesion 449 and epidermal development. Wilkerson and colleagues reported that the classical 450 subtype is related to xenobiotic detoxification, that the Secretory subtype shows 451 association with the expression of immune related genes, NKX2-1 (TTF1), MUC1 and 452 surfactant genes. It is interesting to note that although the secretory subtype is a 453 squamous cell carcinoma subtype, it shows intermediate scores in the 454 Adenocarcinoma factor ( Fig 7B.2 and B.3, and S10 Fig) , which is consistent with the 455 fact that NKX2-1 is expressed in both the Secretory subtype and in adenocarcinomas. 456 Finally, the Primitive subtype has previously been associated with proliferation and 457 DNA processing and repair.
458
Adenocarcinoma and squamous cell carcinoma 459 The differences between adenocarcinoma and squamous cell carcinoma are captured 460 by the Adenocarcinoma factor, which is high in adenocarcinomas and low in 461 19/30 squamous cell carcinomas. Interestingly, in the primitive subtype of squamous cell 462 carcinoma, tumors with high and low values for this factor exist ( Fig 7B.2 and B.3 , and 463 S10 Fig) . In addition, copy number is dominated by a particularly strong negative 464 association with the gain of Chromosome 3q26-29, implying that the 465 adenocarcinomas show absence of gains while squamous cell carcinomas carry this 466 gain (Fig 9) . We also observe the expected associations between this factor and 467 mutations in NFE2L2, STK11, KEAP1. KRAS, EGFR, PTEN, TP53, PIK3CA, BRAF 468 and ARID1A ( Fig 8A) . As expected, the Adenocarcinoma factor is high in all the 469 Wilkerson adenocarcinoma subtypes, as compared to the squamous cell carcinoma 470 subtypes. More specifically, the Adenocarcinoma factor is very low in the Basal and 471 Classical subtypes but higher in the Secretory and Primitive subtypes.
472
Two factors strongly associated with RPPA: BSCC and 8p11 gained 473 The largest fraction of the variance explained by the BSCC and 8p11-gained factors is 474 associated with the RPPA data ( Fig 7A) . In fact, the amount of variation explained in 475 the RPPA data by these two factors is the highest across all factors and all data types. 476 The 8p11-gained factor is associated with increased gain of recurrent aberrations 477 containing the genes NDS3, LETM2 and, FGFR1, which are located on the 8p11 478 chromosomal band (Fig 9) , and shows high scores in the PI subtype. As expected, 479 the BSCC factor shows, in general, higher scores within the Basal subtype as 480 compared to other squamous cell carcinoma subtypes ( S7 Fig and S10 Fig) . 481 Specifically, the BSCC factor shows intermediately strong association with the basal 482 subtype of squamous cell carcinoma (AUC=0.59).
483
DNA replication factor 484 The DNA replication factor captures two biological processes. Pathway analysis 485 reveals a positive association of this factor with pathways involved in DNA replication, 486 implying that genes annotated to these pathways are enriched in tumors with high 487 levels of this factor. According to the Cibersort analysis, this factor is positively 488 correlated with signatures representing activated memory CD4 T-cells and negatively 489 correlation with signatures representing resting mast and resting dendritic cells 490 ( Fig 8B) . Conversely, this factor shows negative association with the protein 491 expression of the transcription factor NKX2-1. As expected, NKX2-1 targets correlates with signatures of γδ T-cells and M1 macrophages ( Fig 8B) . In addition, this 513 factor is associated with an increased loss of 9p23-21. The Infiltrating B-cells factor 514 shows strong association with interferon associated signatures and T-cell pathways in 515 the gene-set enrichment analysis. However, this association is weaker than for the 516 Immune factor. When considering the RNA expression coefficients of this factor we 517 see large coefficients for immunoglobulins, but in contrast to the Immune factor, 518 neither the HLA nor the complement system is represented. This factor has a strong 519 positive correlation with plasma B-cells ( Fig 8B) and is associated with a higher 520 mutation rate of STK11 ( Fig 8A) .
521
As the PP subtype shows overexpression of defense response genes (chemokines), 522 we observe, consistent with this finding, that the infiltrating B-cell and Immune factors 523 score highly in this subtype ( Fig 7B.5 and Fig 7B.7) . In contrast, the Infiltrating B-cell 529 We identified a number of factors with a clear functional profile, but where additional 530 research is required to understand their role and relevance in lung cancer. First, the 531 Mitochondrial factor associated with genes encoded on the mitochondrial DNA and 532 GAPDH protein expression ( Fig 6) . Second, the Translation factor which shows 533 enrichment for translation pathways and signatures of the cell cycle (S4 Fig) . This 534 association is also strongly supported by the large coefficients of genes encoding 535 ribosomal proteins ( Fig 6) . Finally, as in breast cancer, we also identified an EMT 536 factor in lung. As in breast, the EMT lung factor is strongly correlated with the The NFE2L2 factor shows association with NFE2L2 targets in the gene-set 542 enrichment analysis, suggesting this factor captures the activation of NFE2L2. This 543 conclusion is confirmed by a strong association of this factor with mutations in 544 NFE2L2 and in its inhibitor KEAP1 ( Fig 8A) . Interestingly, the factor is depleted for 545 EGFR mutations, although EGFR activates the NFE2L2 pathway by inhibiting 546 KEAP1 [34] . Still, these three genes in the NFE2L2 pathway show a mutually 547 21/30 exclusive mutation pattern (Fig 8C, p<0 .05, DISCOVER groupwise test [35] ), 548 suggesting that they independently activate the NFE2L2 pathway effecting the 549 common downstream gene expression changes captured by this factor. So, this factor 550 could be a readout of NFE2L2 pathway activation, which in some conditions has been 551 suggested to increase resistance to EGFR inhibitors 552 In addition to the clear NFE2L2 association, this factor also shows large values for the 553 coefficients for genes related to xenobiotic detoxification, such as CES1, CYP4F3 and 554 CYP4F11. Hence, it is not surprising that the NFE2L2 factor shows high scores in the 555 Classical subtype, which is also associated with this process.
Mitochrondial, Translation and EMT factors
556
In summary, we have identified factors that do show overall association, but not very 557 clear one-to-one correspondence with the previously defined Wilkerson subtypes. Our 558 factors do capture the major lung cancer subtypes (Adenocarcinoma and Squamous 559 cell carcinoma), and identified processes that occur in both of these types. These 560 include epithelial to mesenchymal transition, two immune processes, and, most 561 interestingly, a factor that reports the activity of the NFE2L2 pathway. The latter may 562 have interesting therapeutic consequences.
563
Discussion
564
In both breast and lung cancer the sparse-factor analysis was able to recover known 565 biology. Additionally, we find factors that capture biology that traditional clustering 566 methods have not been able to find, such as the Immune, EMT, and infiltrating B-cells 567 factors. Our results illustrate the need for continuous factors as opposed to discrete Proliferative factors in breast cancer are mostly copy number driven. Also, the protein 575 expression contributes to key factors such as the ER and HER2 factors.
576
Interestingly we have found the same cancer cell specific EMT factor in both lung and 577 breast cancer. This does not necessarily mean that tumors with high levels of this 578 factor have a large proportion of mesenchymal tumor cells. More likely, this factor 579 represents the activation of a transcriptional program that may eventually lead to a 580 transition to the mesenchymal phenotype. Therefore, the tumors with high levels of 581 this factor can have a higher propensity to undergo EMT. This can potentially be 582 resolved by applying the method pan-cancer including both epithelial and 583 mesenchymal cancers. As the mesenchymal tumors should get a maximum EMT 584 score, this analysis could give an indication how far along the EMT transition the cells 585 in these tumors really are.
586
Several factors may potentially have an application in predicting a tumors' response to 587 treatment. The NFE2L2 factor might be indicative of response to dimethyl fumarate 588 (DMF) treatment, which targets the NFE2L2 pathway and can inhibit 589 carcinogenesis [36] . Because the factor measures activation of the transcription factor 590 through its downstream targets, it could be more predictive than only looking at 591 mutations in the transcription factor itself. This hypothesis could be tested on patient predictive for response to immune checkpoint inhibitors. If the immune system is 595 already highly active, a clinically relevant response might be easier to achieve. These 596 hypotheses can be tested by obtaining RNA expression data from pre-treatment 597 biopsies of patients treated with immune checkpoint inhibitors, scoring these factors 598 based on these data and correlating that with their response to checkpoint inhibitors.
599
In the lung cancer data set we found two highly correlated factors. Without the 600 sparsity penalties, the algorithm should find orthogonal factors. Orthogonal factors 601 explain the most variance, but the sparsity penalties prevent full orthogonality. An 602 explanation of the highly correlating factors can be that the optimal sparsity penalty is 603 different per factor, where one biological process involves thousands of genes, and 604 another only a few.
605
In this study we used only the tumors which have all data types available. With 606 increasing tumors sizes and an increasing number of data types this results in a 607 situation where ever growing parts of the data can not be incorporated in an 608 integrative analysis. The EM framework quite naturally allows for missing data, so this 609 might be an interesting future extension.
610
In addition to the data types we used here, other molecular data types that could be 611 included are DNA methylation and miRNA expression data. As the mutation data 612 includes driver events it would be desirable to include it as well. This would require 613 transforming the mutation data such that it has approximately Gaussian error. One 614 way to do this is by smoothing mutations over an interaction network [37] . The 615 inclusion of higher level tumor phenotypes, such as features obtained from MR 616 imaging or pathology slides, could guide the method towards finding biological 617 processes that lead to clinically relevant differences. 618 We have shown FuncSFA is able to find biological processes that are active across 619 otherwise very different tumors, such as the ER+ and ER-subtypes in breast cancer.
620
Applying this method to a pan-cancer cohort might find biological processes that are 621 activated in a large number of tumor types and provide insight into how tumors of 622 different origin relate to each other.
623
In summary, we have shown that FuncSFA is able to integrate at least three data 624 types. It identifies continuous-valued factors that could be simultaneously active in the 625 same tumor removing the necessity to assign tumors to clusters. Our results illustrate 626 the advantage of factors over clusters with several biologically or clinically relevant 627 examples. The identified factors represent the heterogeneity both within and between 628 cancer types, and represent the activation of biological processes in a patient specific 629 manner. Considering the more complete and fine-grained characterization they allow, 630 these factors could benefit the personalized treatment of cancer.
631
Methods
632
The FuncSFA method consists of two steps. In the first step, a sparse-factor analysis 633 integrates multiple data types into a small number of factors. In the second step, the 634 factors are linked to existing knowledge of biology by doing a gene-set enrichment 635 analysis. 636 
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Additional methods 703 t-SNE [40] was used to summarize the factors in two non-linear dimensions, yielding a 704 high-level map the factors and other tumor variables can be projected on. These 705 t-SNE maps were calculated using scikit-learn [41] . 706 The explained variance of a factor is calculated by subtracting the summed square 707 error of the model with all factors from the model excluding the factor dividing by the 708 total sum of squares of the data:
for factor i and data type t where B t[·,−i] and Z [−i,·] are the coefficients and factors 710 excluding the factor i. The squared Frobenius norm || · || 2 F is the sum of squares of the 711 elements of a matrix.
712
Software and data availability. 713 The software for the sparse-factor analysis is available from 
